Log in to your IBTimes Account

close
ID
Password
  • Set your IBTimes.com Edition

Study: Concerns on mixing Plavix, heartburn drugs



By MATTHEW PERRONE and MARLEY SEAMAN, AP
11 November 2008 @ 05:23 pm EST

NEW YORK - Stent patients who take the blood thinner Plavix along with certain heartburn drugs may face a greater risk of heart attack, stroke and other dangerous events, according to a study released Tuesday.

Related Topic

Get stories by e-mail on this topic.

E-mail:
Quotes
AZN 41.16 -0.37
MHS 43.36 -0.77
BMY 22.18 -0.17
SNY 32.19 0.41
WYE 38.18 -0.38

SYMBOL LOOKUP

Researchers found that patients who were taking Plavix with popular prescription heartburn drugs, including AstraZeneca PLC's Nexium, were significantly more likely to be hospitalized for a heart attack, stroke, chest pain or a coronary artery bypass operation than those who took Plavix alone.

The study followed more than 14,000 patients from 2005 to 2006 in a database kept by pharmacy benefits manager Medco Health Solutions Inc.

Nexium and other proton pump inhibitors, like Wyeth's Protonix, are used to treat chronic heartburn, in which stomach acids come back up the esophagus, causing pain and inflammation. Doctors frequently prescribe these drugs to patients on Plavix because the blood thinner has been linked to a higher risk of ulcers.

Medco said 40 percent of patients in its study were taking the prescription heartburn medications. The company's chief medical officer, Robert Epstein, said that if over-the-counter medications like AstraZeneca's Prilosec were included, the percentage would likely be even higher.

Epstein said heartburn drugs could interfere with a liver enzyme needed to process Plavix, neutralizing its effects.

He stressed that patients should not stop taking Plavix or heartburn drugs, particularly if they have a history of stomach problems.

"But if you're a person who's otherwise healthy taking Plavix, you might want to consider calling your doctor and asking, 'Do I need really need this' or 'Do I need it every day?' " Epstein said in an interview. "There are ways to look at this question now that we wouldn't have thought about previously."

Bristol-Myers also urged patients to talk with their doctor before taking action and questioned Medco's approach.

"While we are still reviewing the data, in general, retrospective analyses--in contrast to randomized clinical trials--are more subject to confounding factors," said spokesman Ken Dominski.

Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

    Click!
  • Rate this article:

Comments

Post Your Comment

You must be an IBTimes member to post a comment. Login | Register



advertisement
More Industries
The financing arm of General Motor's Corp. has until midnight Friday to clear a final hurdle in its quest to become a bank holding company, even though i...
Wall Street put together a moderate advance Friday after the government threw a lifeline to General Motors' financing arm, but gains were limited by drea...
Shares of some top utilities companies were mixed at the close of trading: AEP rose $.29 or .9 percent, to $32.08.

Advertisement
Build Business Credit for your company with NO PERSONAL GUARANTEES!

Building your business and corporate credit for your small business.

Los angeles web design

Get your next web design project done with our los angeles web design team - Best web design with great price.

Checkbook Control of your IRA/401k funds before retirement age- No Tax penalties

Buy Real Estate, Tax Liens, and more- Fund your business or franchise without debt

advertisement
 
IBTimes.com Web
Partners
International Business Times© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives